

# Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis

Adam Booth <sup>1¶</sup> & Angus Bruno Reed <sup>1¶</sup>, Sonia Ponzo <sup>1</sup>, Arrash Yassae <sup>1</sup>, Mert Aral <sup>1</sup>, David Plans <sup>1\*</sup>, Alain Labrique <sup>2</sup>, Diwakar Mohan <sup>2</sup>

<sup>¶</sup>These authors contributed equally.

1. Huma Therapeutics Limited, London, England.
2. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

\* Corresponding Author: David Plans ([david.plans@huma.com](mailto:david.plans@huma.com))

## Disclosure statement

A.B., A.B.R., S.P., D.P., A.Y., M.A., are employees of Huma Therapeutics Ltd.

D.M. & A.L. declare that they have no conflict of interests to report.

## Funding

This research was funded by Huma Therapeutics Ltd.

## Keywords

COVID-19; SARS-CoV-2; severe; risk factors; mortality; meta-analysis; clinical characteristics

# 1 Abstract

2 **Aim:** COVID-19 clinical presentation is heterogeneous, ranging from asymptomatic to severe cases. While  
3 there are a number of early publications relating to risk factors for COVID-19 infection, low sample size and  
4 heterogeneity in study design impacted consolidation of early findings. There is a pressing need to identify the  
5 factors which predispose patients to severe cases of COVID-19. For rapid and widespread risk stratification,  
6 these factors should be easily obtainable, inexpensive, and avoid invasive clinical procedures. The aim of our  
7 study is to fill this knowledge gap by systematically mapping all the available evidence on the association of  
8 various clinical, demographic, and lifestyle variables with the risk of specific adverse outcomes in patients with  
9 COVID-19.

10 **Methods:** The systematic review was conducted using standardized methodology, searching three electronic  
11 databases (PubMed, Embase, and Web of Science) for relevant literature published between 1<sup>st</sup> January 2020  
12 and 9<sup>th</sup> July 2020. Included studies reported characteristics of patients with COVID-19 while reporting outcomes  
13 relating to disease severity. In the case of sufficient comparable data, meta-analyses were conducted to estimate  
14 risk of each variable.

15 **Results:** Seventy-six studies were identified, with a total of 17,860,001 patients across 14 countries. The  
16 studies were highly heterogeneous in terms of the sample under study, outcomes, and risk measures reported. A  
17 large number of risk factors were presented for COVID-19. Commonly reported variables for adverse outcome  
18 from COVID-19 comprised patient characteristics, including age >75 (OR = 2.65 (1.81–3.90)), male sex (OR =  
19 2.05(1.39–3.04)) and severe obesity (OR = 2.57 (1.31–5.05)). Active cancer (OR = 1.46 (1.04–2.04)) was  
20 associated with increased risk of severe outcome. A number of common symptoms and vital measures  
21 (respiratory rate and SpO<sub>2</sub>) also suggested elevated risk profiles.

22 **Conclusions:** Based on the findings of this study, a range of easily assessed parameters are valuable to  
23 predict elevated risk of severe illness and mortality as a result of COVID-19, including patient characteristics  
24 and detailed comorbidities, alongside the novel inclusion of real-time symptoms and vital measurements.

## 25 Introduction

26 SARS-CoV-2, first reported to the WHO on 31 December 2019, has subsequently exponentially spread with  
27 cases now officially reported in 215 countries and territories [1]. Following infection, individuals may develop  
28 COVID-19, an influenza-like illness targeting, primarily, the respiratory system. The clinical pathophysiology  
29 of COVID-19 is still the subject of ongoing research. It is clear, however, that clinical presentation is  
30 heterogeneous, ranging from asymptomatic to severe disease. Evidence suggests most patients move through  
31 two phases: (a) viral replication over several days with relatively mild symptoms; (b) adaptive immune response  
32 stage, which may cause sudden clinical deterioration [2]. Severe symptoms are thought to be the consequence of  
33 the SARS-CoV-2 virus invading type II alveolar epithelial cells, causing the release of cytokines and  
34 inflammatory markers. This ‘cytokine storm’ attracts neutrophils and T cells, which in turn cause significant  
35 lung injury and inflammation, eventually leading to acute respiratory distress syndrome [3]. There are a number  
36 of different classifications of COVID-19, with recent attempts to sub-divide intensive care patients into different  
37 clinical phenotypes [4]. Guidelines for the classification of COVID-19 disease severity in adults were first  
38 reported in February 2020 and have since been widely adopted internationally [5]. Reported complications and  
39 long-term sequelae in survivors are varied and include neurologic, hematologic, musculoskeletal,  
40 cardiovascular, and GI-related issues [6]. While most patients recover quickly, a growing number are suffering  
41 from so-called ‘long COVID’, a multisystem, post-viral condition with symptoms including fatigue, anxiety,  
42 low mood, cognitive problems, and atypical chest pain, stretching over a period of weeks or months without  
43 recovery [7]. In addition, mental health conditions (e.g. PTSD, depression, and anxiety) are also known to result  
44 from extended ICU admission [8].

45 COVID-19 has posed unprecedented care and logistic challenges, with resource-intense care settings such as  
46 critical care having to increase capacity by up to 300% [9]. This has significant downstream effects on wider  
47 healthcare capacity, including the delivery of elective surgical care and mental health services [10]. For  
48 example, DATA-CAN estimates that the impact of reducing access to cancer screening, triage, and treatment  
49 will result in a further 7,165-17,910 excess deaths amongst the UK population within one year [11]. It is for this  
50 reason that many national strategies have focused, from the outset, on preventing health systems becoming  
51 overloaded by clinical demand [12].

52 The ability to predict the likelihood of severe health outcomes in patients affected by COVID-19 has the  
53 potential to inform decision-making at the individual, provider, and government level. At the patient level,  
54 accurate prognostication could facilitate evidence-based decisions around shielding. At a provider level,  
55 predictors of severity, if coupled with epidemiological models, could enable accurate scenario planning and  
56 inform resource allocation decisions. At a governmental level, population-wide risk assessments could help  
57 inform the targeted use of non-pharmacological interventions, potentially minimising the economic and  
58 population health impact of wide-sweeping social distancing measures. Furthermore, with news that national  
59 governments have begun procuring COVID-19 vaccines, an evidence-based risk stratification tool could help  
60 policymakers decide which segments of the population to prioritise in national vaccination programmes [13].

61 Although serologic biomarkers are useful in grading the severity of a COVID-19 case upon admission to the  
62 hospital, patients are often experiencing severe disease by the time they present clinically. The ability to stratify  
63 cases earlier in the disease process (based on demographics and lifestyle factors) could prove invaluable to  
64 initiating earlier referrals and possibly improving patient outcomes. To allow rapid and widespread risk  
65 stratification, these factors should be easily obtainable, inexpensive, and avoid invasive clinical procedures.  
66 These factors should also help shape decision-making at an individual, provider, and system level. To this end,  
67 we included symptom information in our analysis on the grounds that individuals isolating at home with  
68 COVID-19, along with their clinical team, can be informed about their risk of deterioration as and when new  
69 symptoms develop. Retrospective cohort data suggest that many patients present to hospital more than seven  
70 days after onset of symptoms, potentially offering providers some, albeit short, notice to prioritise resources if  
71 necessary [14]. In contrast, blood tests are only likely to be of value in stratifying disease severity amongst those  
72 patients already severe enough to require hospitalisation. Blood test data would, therefore, provide limited use  
73 for individuals' behaviour modification or remote monitoring, and is unlikely to help providers anticipate  
74 increased clinical demand.

75 However, there are challenges in creating such a prognostic tool based on individual or small numbers of  
76 studies. While the volume of academic reporting on clinical features of COVID-19 has been unprecedented, low  
77 sample size and heterogeneity in study design impacted the consolidation of early findings. Early reports on  
78 clinical features were limited to Wuhan, China [15], and the lack of geographical, cultural, and ethnic diversity  
79 has restricted the generalisability of findings. As such, the aim of our study is to fill this knowledge gap by  
80 systematically mapping all the available evidence on the association of various clinical, demographic, and  
81 lifestyle variables with the risk of specific adverse outcomes in patients with COVID-19.

## 82 **Methods**

83 This protocol is in line with the recommendations outlined in the Preferred Reporting Items for Systematic  
84 Reviews and Meta-Analyses (PRISMA) statement.

### 85 **Eligibility criteria**

86 Peer-reviewed observational studies published between 1<sup>st</sup> January 2020 and 9<sup>th</sup> July 2020 in the English  
87 language were included. Only papers reporting original data on adult (>16 years old) patients with laboratory-  
88 confirmed SARS-CoV-2 were selected. The minimum sample size for inclusion was 100 patients. Narrative  
89 reviews, case reports, papers only reporting laboratory or imaging data, and papers not reporting original data  
90 were not included. Studies including homogeneous populations with exclusion criteria (e.g. female patients  
91 pregnant at the time the study was conducted) were also excluded.

### 92 **Information sources and search strategy**

93 A systematic review using PubMed, EMBASE, and Web of Science was conducted. Additionally, a  
94 thorough hand search of the literature and review of the references of included papers in the systematic review

95 was carried out to minimize the likelihood that the used search terms did not identify all relevant papers. The  
96 following search terms were included: ncov\* OR coronavirus OR "SARS-CoV-2" OR "covid-19" OR  
97 covid, AND ventilator OR ICU OR "intensive care" OR mortality OR prognosis OR ARDS OR severity  
98 OR prognosis OR hospitalis\* OR hospitaliz\* OR "respiratory failure" OR intubation OR ventilation OR  
99 admission\* OR admitted OR "critical care" OR "critical cases", AND clinical OR symptom\* OR  
100 characteristic\* OR comorbidit\* OR co morbidit\* OR risk OR predict\* and "PUBYEAR > 2019".  
101 Comprehensive search terms can be found in supplementary material (S1 Table).

## 102 **Study selection**

103 Two authors (A.B.R. and A.B.) independently reviewed titles and abstracts to ascertain that all included  
104 articles were in line with the inclusion criteria (Fig. 1). Studies with missing, unclear, duplicated, or incomplete  
105 data were excluded from the review. Observational studies including original data on at least 100 adult patients  
106 with laboratory-confirmed SARS-CoV-2, whether hospitalised or in outpatient settings, were included in the  
107 meta-analysis.

## 108 **Data collection process and data items**

109 The following information was extracted from each selected article: author, publication year, article title,  
110 location of study, SARS-CoV-2 case identification, study type (e.g. primary research, review, etc), peer-review  
111 status, quality assessment, and total sample size. Extracted data included sample demographics (age, sex,  
112 ethnicity), obesity/BMI status, smoking status, blood type, any existing comorbidities, symptoms, basic clinical  
113 variables (e.g. heart rate, respiration rate, and oxygen saturation), and their clinical outcomes of severe (severe  
114 case definition, admission to ICU, invasive mechanical ventilation (IMV), and death) versus non-severe  
115 comparator event (e.g. no ICU admission, survival/recovery). Data extraction was carried out using software  
116 specifically developed for systematic review (Covidence, Veritas Health Innovation, Melbourne, Australia).

117 **Fig 1. PRISMA diagram.**

## 118 **Assessment of methodological quality and risk of bias**

119 An adapted version of the Newcastle-Ottawa Scale [16] was used during full-text screening to assess the  
120 methodological quality of each article. Two authors reviewed the quality of included studies (A.B.R. and A.B.),  
121 with conflicts resolved in consensus. Studies were judged on three criteria: selection of participants;  
122 comparability of groups; and ascertainment of the exposure and outcome of interest.

## 123 **Statistical approach**

124 Reported measures relating to patient characteristics, comorbidities, symptoms, and vital signs were  
125 extracted from included articles. We analysed similar risk metrics for each outcome and pooled extracted values.  
126 Where possible, a meta-analysis was carried out to assess the strength of association between reported risk  
127 factors and two outcomes: severe and mortality. Severe outcome was defined as the clinical definition of severe,

128 ICU admission, or IMV, while excluding hospitalisation. If a study reported multiple outcomes, then the clinical  
129 definition of severe [17,18] was taken to avoid duplication of data. Meta-analysis regression of reported  
130 multivariate Odd Ratios (ORs) were pooled with estimated effect size calculated using a random-effects model.

131 To accommodate for heterogeneity across the studies, we estimated risk weighting for each reported variable  
132 across two endpoints: severe COVID-19 (comprising severe case definition, ICU admission, and IMV) and  
133 mortality from COVID-19. If at least two studies reported ORs (multivariate or univariate) for the same clinical  
134 variable, pooled weighted estimates were calculated on the basis of sample size and standard error. Data were  
135 analysed using the R statistical software [19]. The meta-analysis and plots were created using the R package  
136 *meta* [20].

## 137 **Results**

138 The comprehensive search of databases and cross-referencing hand search identified 2122 articles meeting  
139 the search criteria, following removal of duplicates. During screening of title and abstract, 1991 articles were  
140 excluded. Consequently, 131 articles were selected for full-text review. Of these, 76 articles were deemed to  
141 meet the inclusion/exclusion criteria. Articles were excluded for the following primary reasons: repeated data  
142 (n=19); wrong design/outcome of interest (n=18); insufficient sample size (n=7); homogenous population (n=6);  
143 and editorial or commentary (n=5) (full reasoning is noted in Fig. 1). A summary of all included studies'  
144 characteristics and quality assessment is given in Table 1. Inter-rater reliability of article inclusion was  
145 substantial ( $\kappa=0.74$ ).

146 Research was pooled from 14 geographies with China the most commonly reported (n=43) [14,21–33,33–  
147 62], followed by USA (n=15) [63–77], Italy (n=4) [78–81], and UK (N=3) [82–84]. The remaining papers were  
148 from Mexico [85,86], South Korea [87,88], Turkey [89], Brazil [90], Denmark [91], France [92], Israel [93],  
149 Iran [94], and Poland [95]. A total of 17,860,001 subjects are described in the included studies; however, after  
150 excluding two large national cohort studies which involved non-COVID-19 subjects [83,84], the final sample  
151 included data on 153,115 reported individuals with COVID-19.

152 Reported outcomes across studies varied and were categorised into five grouped endpoints: severe,  
153 hospitalisation, ICU admission, IMV, composite endpoint (considered as ICU, IMV, or mortality), and  
154 mortality.

155 The literature reported a wide variety of variables that may provide insight to estimate risk of adverse  
156 outcomes in COVID-19. These variables were grouped into four categories: patient characteristics,  
157 comorbidities, presenting symptoms, and vital signs (Table 1). Univariate ORs were reported, or calculated  
158 where sufficient data was presented, in 65 articles. Multivariate ORs were reported in 45 studies, while 17  
159 reported Hazard Ratios and two reported Risk Ratios.

**Table 1.** Summary of studies

Study	Publication date	Country	Study design	Sample size (n)	Severe	Non-severe comparator	Patient characteristics	Comorbidities	Symptoms	Vital signs	Study Quality (mNOS)
Argenziano 2020 [63]	29/05/2020	United States	Retrospective single-centre, case series	1000	ICU	ER, hospital (non-ICU)	Male, Age, BMI, Smoking, Ethnicity	Any comorbidity, Hypertension, CVD, Diabetes, Cerebrovascular Disease, Chronic Liver Disease, Asthma, COPD, Sleep Apnoea, Active Cancer, Interstitial Lung Disease, CKD, Transplant history, Rheumatic Disease, Chronic Lung Disease, Viral Hepatitis, HIV	Fever, Myalgia, Cough, Sputum, Dyspnoea, Nausea, Diarrhoea, Pharyngalgia, Headache, Chills, Rhinorrhoea		6
Baqui 2020 [90]	02/07/2020	Brazil	Retrospective multi-centre, cross sectional study	11321	Mortality	Survived/Recovered	Male, Age, BMI, Ethnicity	CVD, Diabetes, Chronic Liver Disease, Chronic Lung Disease, Asthma, Immunosuppression, CKD, Neurological Disease			9
Bello-Chavolla 2020 [85]	01/07/2020	Mexico	Retrospective multi-centre, cross sectional study	51,633	Mortality	Survived/Recovered	Age, BMI	Diabetes, Chronic Lung Disease, Immunosuppression, CKD	Haemoptysis		10
Cao 2020 [21]	13/03/2020	China	Retrospective single-centre, case series	102	Mortality	Survived/Recovered	Male	Any comorbidity, Hypertension, CVD, Cerebrovascular Disease, Chronic Liver Disease, Chronic Lung Disease, Active Cancer, CKD	Fever, Fatigue, Myalgia, Cough, Diarrhoea		6
Chen 2020 [22]	19/03/2020	China	Retrospective single-centre, case series	249	ICU	Non-ICU	Male, Age	Any comorbidity			10
Chen 2020 [23]	26/03/2020	China	Retrospective single-centre,	274	Mortality	Survived/Recovered	Male, Age, Smoking	Any comorbidity, Hypertension, CVD,	Fever, Fatigue, Myalgia, Cough,	Respiratory Rate, Heart	6

**Table 1. Summary of studies**

			case series					Diabetes, Chronic Lung Disease, Active Cancer, Immunosuppression, CKD, Chronic GI, Viral Hepatitis	Sputum, Dyspnoea, Chest pain, Nausea, Pharyngalgia, Headache, Dizziness, GI, Anorexia	Rate, Oxygen saturation %
Chen 2020 [24]	16/06/2020	China	Retrospective multi-centre, case series	1859	Mortality	Survived/Recovered	Age, Smoking		Fever	9
Cummings 2020 [64]	19/05/2020	United States	Retrospective multi-centre, case series	257	Mortality	Survived/Recovered	Male, Age	Hypertension, CVD, Diabetes, Chronic Lung Disease		9
D'Silva 2020 [65]	26/05/2020	United States	Retrospective, single-centre comparative cohort study	156	1. Hospitalisation 2. Composite endpoint: Mechanical ventilation/intensive care admission 3. Mortality	1. Non-hospitalisation 2. Non-mechanical ventilation/intensive care admission 3. Survival		Rheumatic Disease		9
Dai 2020 [25]	28/04/2020	China	Retrospective, multi-centre comparative cohort study	641	1. Severe symptoms 2. Intensive care admission 3. Invasive Mechanical Intervention 4. Mortality	1. Mild symptoms 2. Non-intensive care admission 3. Non-invasive Mechanical Intervention 4. Survival		Active Cancer		6
Deng 2020 [26]	25/02/2020	China	Retrospective multi-centre, case series	225	Mortality	Survived/Recovered	Male	Any comorbidity, Hypertension, CVD, Diabetes, Chronic Lung Disease	Fever, Fatigue, Cough, Sputum, Dyspnoea	7
Docherty 2020 [82]	22/05/2020	UK	Prospective multi-centre cohort study	20133	Mortality	Discharged	Male, Age, BMI	CVD, Diabetes, Chronic Liver Disease, COPD, Active Cancer, CKD, Dementia, Neurological Disease	Diarrhoea	10
Du 2020 [27]	08/04/2020	China	Retrospective single-centre, case series	179	Mortality	Survived/Recovered	Male, Age	Hypertension, CVD, Diabetes, Chronic GI	Fatigue, Myalgia, Cough, Sputum, Dyspnoea,	8



Table 1. Summary of studies										
									Headache, GI	
Ellinghaus 2020 [81]	17/06/2020	Italy and Spain	Retrospective multi-centre, genome-wide association study	3815	Respiratory failure	No respiratory failure	Blood Type			10
Feng 2020 [28]	01/06/2020	China	Retrospective multi-centre, case series	476	Severe & critical disease (5th ed. COVID-19 guidelines NHC)	Moderate disease (5th ed. COVID-19 guidelines NHC)	Male, Age, Smoking, Alcohol Intake	Any comorbidity, Hypertension, CVD, Diabetes, Cerebrovascular Disease, COPD, Immunosuppression, CKD, Others	Fever, Myalgia, Cough, Sputum, Dyspnoea, Chest pain, Pharyngalgia, GI, Haemoptysis, Chills	7
Göker 2020 [89]	23/06/2020	Turkey	Retrospective single-centre, case series	186	Composite endpoint: Intubation, ICU or Mortality	Undefined	Blood Type			7
Giacomelli 2020 [78]	22/05/2020	Italy	Prospective single-centre, case series	233	Mortality	Survived/Recovered	Male, Age, BMI, Smoking	Any comorbidity	Fever, Cough, Dyspnoea, Nausea	Haemoglobin Levels 10
Grasselli 2020 [79]	28/04/2020	Italy	Retrospective multi-centre, case series	1591	Mortality	Discharged or still in ICU	Age	Hypertension		6
Guan 2020 [29]	14/05/2020	China	Retrospective multi-centre, case series	1590	Composite endpoint: ICU, Intubation or Mortality	Non-ICU or survivor		Any comorbidity, Hypertension, CVD, Diabetes, Cerebrovascular Disease, COPD, Active Cancer, Immunodeficiency, CKD, Others		10
Gupta 2020 [66]	06/08/2020	United States	Retrospective multi-centre, case series	2215	Mortality within 28 day of ICU admission	Survival within 28 day of ICU admission	Male, Age, BMI, Smoking, Ethnicity	Any comorbidity, Hypertension, CVD, Diabetes, Chronic Lung Disease, Asthma, COPD, Active Cancer, Immunodeficiency, CKD	Fever, Fatigue, Cough, Sputum, Nausea	9
Hajifathalian 2020 [67]	05/08/2020	United States	Retrospective multi-centre, case series	770	Composite endpoint: ICU or Mortality	Non-ICU or survivor	Age, BMI, Ethnicity			10

**Table 1.** Summary of studies

Hou 2020 [87]	23/06/2020	South Korea	Retrospective single-centre, case series	211	Progression to severe stage COVID-19	Asymptomatic or mildly symptomatic patients who were discharged	Male, Age	Hypertension, Diabetes	Fever, Myalgia, Cough, Sputum, Dyspnoea, Chest pain, Diarrhoea, Pharyngalgia, Headache, Chills, Rhinorrhoea	10
Huang 2020 [30]	08/05/2020	China	Retrospective multi-centre, case series	202	Severe disease (5th ed. COVID-19 guidelines NHC)	Non-severe disease (5th ed. COVID-19 guidelines NHC)	Male, Age, BMI, Smoking	Any comorbidity, Hypertension, Chronic Heart Disease, Diabetes	Fever, Fatigue, Cough, Dyspnoea, Pharyngalgia	9
Huang 2020 [31]	01/06/2020	China	Retrospective multi-centre, case series	310	1. Severe (5th ed. COVID-19 guidelines NHC) 2. Mortality	1. Non-severe 2. Survival	Male, Age	Hypertension	Nausea	10
Imam 2020 [68]	04/06/2020	United States	Retrospective multi-centre, case series	1305	Mortality	Survived/Recovered	Male, Age, Smoking	Hypertension, CVD, Diabetes, Cerebrovascular Disease, Chronic Liver Disease, Asthma, COPD, Sleep Apnoea, Active Cancer, Immunosuppression, CKD, Dementia		10
Israelsen 2020 [91]	15/05/2020	Denmark	Retrospective single-centre, case series	175	ICU	General ward treatment				6
Itelman 2020 [93]	01/05/2020	Israel	Retrospective single-centre, case series	162	Severe - defined as requiring intensive help for proper oxygenation (high-flow oxygen delivery device or artificial ventilation, either non-invasive or invasive)	Mild or Moderate disease (flu-like without clinical and imaging signs of pneumonia; pneumonia and hypoxemia)	Male	Hypertension, Chronic Heart Disease, Diabetes		4
Jin 2020 [32]	01/06/2020	China	Retrospective multi-centre, case series	651	Severe/Critical disease (6th ed. COVID-19 guidelines NHC)	Mild/Moderate disease (6th ed. COVID-19 guidelines NHC)			Sputum, GI	9
Kalligeros 2020 [69]	02/06/2020	United States	Retrospective multi-centre,	103	1. ICU admission within the first 10	1. No ICU admission within the first 10 days	Male, Age, BMI, Smoking,	Hypertension, Chronic Heart		10

**Table 1.** Summary of studies

			case series		days 2. IMV during the first 10 days	2. No IMV during the first 10 days	Ethnicity	Disease, Diabetes, Chronic Lung Disease	
Kammar- García 2020 [86]	25/05/2020	Mexico	Retrospective multi-centre, case series	13842	1. Mortality 2. Composite endpoint: Hospitalization, pneumonia, intubation, and ICU admission	1. Survival 2. Outpatient	BMI	Hypertension, CVD, Diabetes, Asthma, COPD, Immunosuppression, CKD	9
Kim 2020 [70]	16/07/2020	United States	Retrospective multi-centre, case series	2,490	1. ICU 2. Mortality	Hospitalisation without event	Male, Age, BMI, Smoking, Ethnicity	Hypertension, CVD, Diabetes, Chronic Lung Disease, Immunosuppression, CKD, Neurological Disease, Rheumatic Disease	10
Lassale 2020 [83]	01/06/2020	UK	Retrospective multi-centre, cohort study	428494	Hospitalisation	Non-hospitalised	Male, Age, BMI, Smoking, Ethnicity, Alcohol Intake	Hypertension, CVD, Chronic Lung Disease	10
Latz 2020 [71]	12/07/2020	United States	Retrospective multi-centre, case series	1289	Composite endpoint: intubation and death	Hospitalisation without event	Blood Type		10
Lee 2020 [88]	06/05/2020	Korea	Retrospective multi-centre, case series	3191	Severe and critical disease (Daegu Severity Score for COVID-19)	Mild & moderate disease		Loss of smell/taste	6
Li 2020 [96]	08/04/2020	China	Retrospective multi-centre, case series	132	Mortality	Survived/Recovered	Male, Age		10
Li 2020 [34]	29/05/2020	China	Retrospective single-centre, case series	453	Mortality	Survived/Recovered		Diabetes	9
Li 2020 [35]	11/06/2020	China	Retrospective multi-centre, case series	1449	Mortality	Survived/Recovered	Male, Age, Smoking	Fatigue, Myalgia, Cough, Sputum, Dyspnoea, Nausea, Diarrhoea, Headache, Chills	Haemoglobin Levels 6
Liang 2020 [36]	12/05/2020	China	Retrospective multi-centre,	1590	Composite endpoint: ICU,	Hospitalisation without event	Male, Age, Smoking	Any comorbidity, Hypertension, CVD, Fever, Fatigue, Myalgia, Cough,	10

Table 1. Summary of studies												
			case series		ventilation, or death			Diabetes, Cerebrovascular Disease, COPD, Active Cancer, CKD	Dyspnoea, Pharyngalgia, Headache, Haemoptysis, Chills, Unconsciousness			
Liu 2020 [38]	14/04/2020	China	Retrospective single-centre, case series	140	Severe (7th ed. COVID-19 guidelines NHC)	Mild disease	Male, Age	Hypertension, CVD	Fever, Fatigue, Myalgia, Cough, Dyspnoea, Chest pain, Anorexia			6
Liu 2020 [37]	27/04/2020	China	Retrospective single-centre, case series	134	Severe (7th ed. COVID-19 guidelines NHC & American Thoracic Society)	Non-severe disease	Male	Hypertension, Diabetes	Fever, Fatigue, Cough, Sputum, Anorexia			8
Masetti 2020 [80]	14/06/2020	Italy	Retrospective single-centre, case series	229	Mortality	Discharged survivors	Male, Age	Any comorbidity, Hypertension, Chronic Heart Disease, Diabetes, COPD, Active Cancer, CKD				9
Nowak 2020 [95]	18/05/2020	Poland	Retrospective single-centre, case series	169	Mortality	Survived/Recovered	Male, Age	Hypertension, CVD, Diabetes, COPD, Active Cancer, CKD, Others	Fever, Fatigue, Cough, Dyspnoea, Nausea, Diarrhoea			8
Okoh 2020 [72]	10/06/2020	United States	Retrospective single-centre, case series	251	Mortality	Survived/Recovered	Male, Age, Ethnicity	Hypertension, CVD, Diabetes, Cerebrovascular Disease, COPD, Active Cancer, CKD	Fever	Respiratory Rate, Heart Rate, Haemoglobin Levels		9
Palaiodimos 2020 [73]	15/05/2020	United States	Retrospective single-centre, case series	200	1. Increasing Oxygen 2. Intubation 3. Mortality	ICU admission without event	Male, Age, BMI, Smoking, Ethnicity, Alcohol Intake	Hypertension, CVD, Diabetes, Cerebrovascular Disease, Asthma, COPD, Sleep Apnoea, Active Cancer, Immunosuppression, CKD				9
Pei 2020 [39]	29/05/2020	China	Retrospective single-centre, case series	333	Severe/Critical (7th ed. COVID-19 guidelines NHC)	Moderate (7th ed. COVID-19 guidelines NHC)	Male	Hypertension, Diabetes	Fever, Cough, Dyspnoea, Diarrhoea			6
Petrilli 2020	01/05/2020	United	Retrospective	5279	1. Hospitalisation	Non-hospitalised; alive	Male, Age,	Hypertension, CVD,	Fever, Fatigue	Oxygen		10

Table 1. Summary of studies											
[74]		States	single-centre, case series			2. Composite endpoint: intensive care unit, mechanical ventilation, discharge to hospice, or death	BMI, Smoking, Ethnicity	Diabetes, Asthma, COPD, Active Cancer, CKD, Hyperlipidaemia	saturation %		
Price-Haywood 2020 [75]	25/06/2020	United States	Retrospective multi-centre, case series	3481	1. Hospitalisation 2. Composite endpoint: intensive care unit, mechanical ventilation, discharge to hospice, or death	Non-hospitalised; alive	Male, Age, BMI, Ethnicity		Respiratory Rate	10	
Qin 2020 [40]	29/05/2020	China	Retrospective multi-centre, case series	1875	1. Severe 2. Mortality	Non-hospitalised; alive		Cerebrovascular Disease		8	
Ramlall 2020 [76]	03/08/2020	United States	Retrospective multi-centre, case series	6393	1. Intubation 2. Mortality	Hospitalisation without event	Age, BMI, Smoking	Hypertension, CVD, Diabetes, Coagulation disorder, Macular Degeneration	Cough	10	
Ren 2020 [41]	11/05/2020	China	Retrospective single-centre, case series	151	Severe (6th ed. COVID-19 guidelines NHC)	Mild (6th ed. COVID-19 guidelines NHC)	Male	Hypertension, CVD, Diabetes	Fever, Fatigue, Cough, Sputum, Dyspnoea, Nausea, Diarrhoea, Anorexia	10	
Ruan 2020 [42]	03/03/2020	China	Retrospective single-centre, case series	150	Mortality	Survived/Recovered	Male	Hypertension, CVD, Diabetes, Cerebrovascular Disease	Fever, Fatigue, Myalgia, Cough, Sputum, Dyspnoea	5	
Shahriarirad 2020 [94]	18/06/2020	Iran	Retrospective single-centre, case series	113	1. Severe (American Thoracic Society) 2. Mortality	Non-severe; alive	Male	Hypertension, CVD, Diabetes	Fever, Fatigue, Myalgia, Cough, Sputum, Dyspnoea, Chest pain, Nausea, Diarrhoea, Headache, Dizziness, Chills, Anorexia	Oxygen saturation %	6
Shi 2020 [43]	18/03/2020	China	Retrospective single-centre,	487	Severe (undefined)	Mild (undefined)	Male, Age	Hypertension		9	

<b>Table 1. Summary of studies</b>											
			case series								
Shi 2020 [44]	28/04/2020	China	Retrospective multi-centre, case series	306	Mortality	Survived/Recovered	Male	Hypertension, CVD	Fever, Fatigue, Cough, Dyspnoea, Anorexia		5
Simonnet 2020 [92]	09/04/2020	France	Retrospective single-centre, cohort study	124	Ventilation	ICU with no mechanical ventilation	Male, Age, BMI	Hypertension, Diabetes			9
Suleyman 2020 [77]	16/06/2020	United States	Retrospective single-centre, case series	463	1. Hospitalisation 2. ICU 3. Mechanical ventilation	Hospitalisation without event	Male, Age, BMI, Smoking, Ethnicity	Hypertension, CVD, Diabetes, Asthma, COPD, Sleep Apnoea, Active Cancer, CKD	Fever, Myalgia, Cough, Dyspnoea, Nausea, Diarrhoea, Headache, Loss of smell/taste, Anorexia	Respiratory Rate	10
Wang 2020 [47]	20/02/2020	China	Retrospective single-centre, case series	138	ICU	Non-ICU	Male	Any comorbidity, Hypertension, CVD, Diabetes, Cerebrovascular Disease, COPD, Active Cancer, CKD	Fatigue, Myalgia, Cough, Sputum, Dyspnoea, Nausea, Diarrhoea, Pharyngalgia, Headache, Dizziness, Anorexia		6
Wang 2020 [46]	30/03/2020	China	Retrospective single-centre, case series	339	Mortality	Survived/Recovered (at 4 weeks)	Male	Hypertension, CVD, Diabetes, Cerebrovascular Disease, COPD	Fever, Fatigue, Cough, Sputum, Dyspnoea, Diarrhoea, Anorexia		7
Wang 2020 [45]	08/04/2020	China	Retrospective single-centre, case series	344	Mortality	Survived/Recovered	Male, Age	Hypertension, CVD, Diabetes, COPD	Fever, Fatigue, Cough, Sputum, Dyspnoea, Diarrhoea, Anorexia		10
Wang 2020 [48]	11/04/2020	China	Retrospective single-centre, case series	125	Critical (5th ed. COVID-19 guidelines NHC)	Non-critical	Male	Any comorbidity			9
Wang 2020 [49]	30/04/2020	China	Retrospective single-centre, case series	107	Mortality	Survived/Recovered	Male, Age	Hypertension, CVD			7
Williamson	08/07/2020	UK	Retrospective	17,278,392	Mortality	Survived/Recovered	Male, Age,	Hypertension,			8

Table 1. Summary of studies												
2020 [84]			multi-centre, cohort study		BMI, Smoking, Ethnicity	Chronic Heart Disease, Diabetes, Cerebrovascular Disease, Chronic Liver Disease, Chronic Lung Disease, Asthma, Active Cancer, Immunosuppression, CKD, Dementia, Neurological Disease, Transplant history, Rheumatic Disease, Chronic GI						
Wu 2020 [50]	19/05/2020	China	Retrospective single-centre, case series	1048	Composite endpoint: ICU, mechanical ventilation, or death				COPD		9	
Xie 2020 [51]	13/04/2020	China	Retrospective single-centre, case series	140	Mortality	Survived/Recovered			Any comorbidity, Hypertension	Dyspnoea	Oxygen saturation %	8
Yan 2020 [52]	06/04/2020	China	Retrospective single-centre, case series	193	Mortality	Survived/Recovered	Male		Hypertension, Diabetes			6
Yang 2020 [53]	25/05/2020	China	Retrospective single-centre, case series	200	ICU	Non-ICU	Male, Age, Smoking		Any comorbidity, Hypertension, Chronic Heart Disease, Diabetes, Chronic Lung Disease, Active Cancer, CKD	Fever, Fatigue, Myalgia, Cough, Dyspnoea, Nausea, Diarrhoea, Pharyngalgia, Headache, Chills		7
Yao 2020 [54]	24/04/2020	China	Retrospective single-centre, case series	108	Severe (American Thoracic Society)	Non-severe (American Thoracic Society)	Male, Age, Smoking		Any comorbidity, Hypertension, CVD, Diabetes, Chronic Liver Disease	Fever, Fatigue, Cough, Sputum, Dyspnoea, Diarrhoea		10
Ye 2020 [55]	13/06/2020	China	Retrospective multi-centre, case series	856	1. Severe (6th ed. COVID-19 guidelines NHC) 2. ICU 3. Mortality	Mild; hospitalised non-event			Any comorbidity, Hypertension, Chronic Heart Disease, Diabetes, Active Cancer, CKD, Viral Hepatitis, Others			10
Yu 2020 [56]	27/04/2020	China	Retrospective multi-centre,	421	Composite severity outcome (ICU,	No composite endpoint	Male, Age		Hypertension, Chronic Heart	Fever, Cough, Sputum		9

**Table 1.** Summary of studies

			case series		ARDS, or shock)			Disease, Diabetes		
Zhang 2020 [59]	15/03/2020	China	Retrospective multi-centre, case series	645	Severe / Critical (5th ed. COVID-19 guidelines NHC)	Mild to moderate disease (5th ed. COVID-19 guidelines NHC)	Male	Any comorbidity	Fever, Fatigue, Myalgia, Cough, Sputum, Dyspnoea, Nausea, Diarrhoea, Pharyngalgia	10
Zhang 2020 [57]	05/04/2020	China	Retrospective single-centre, case series	221	Severe (American Thoracic Society)	Non-severe (American Thoracic Society)	Male, Age	Any comorbidity, Hypertension, CVD, Cerebrovascular Disease, Chronic Liver Disease, COPD, Active Cancer, Immunosuppression, CKD	Fever, Fatigue, Cough, Dyspnoea, Chest pain, Diarrhoea, Pharyngalgia, Headache, Anorexia	8
Zhang 2020 [58]	15/04/2020	China	Retrospective single-centre, case series	663	1. Severe COVID-19 (National Health Commission definition (trial version 5)) 2. Mortality	1. Mild/Moderate COVID-19 (National Health Commission definition (trial version 5)) 2. Survival	Male, Age	CVD, Chronic Lung Disease, Active Cancer, Endocrine System Disease, Endocrine System Disease, Chronic GI	Fever, Fatigue, Myalgia, Cough, Sputum, Dyspnoea, Chest pain, Nausea, Diarrhoea, Headache, Dizziness	Haemoglobin Levels 9
Zhang 2020 [60]	26/04/2020	China	Retrospective single-centre, case series	111	Composite endpoint: ICU or death.	Discharge	Male	Any comorbidity, Hypertension, Diabetes	Fever, Fatigue, Myalgia, Cough, Dyspnoea, Chest pain, Diarrhoea	Respiratory Rate 10
Zheng 2020 [97]	24/03/2020	China	Retrospective single-centre, case series	161	Severe COVID-19 (National Health Commission definition (trial version 5))	Non-severe COVID-19 (National Health Commission definition (trial version 5))	Male	Hypertension, CVD, Diabetes, Cerebrovascular Disease, COPD	Fever, Fatigue, Myalgia, Cough, Dyspnoea, Diarrhoea, Headache	7
Zhou 2020 [14]	09/03/2020	China	Retrospective single-centre, case series	191	Mortality	Survived/Recovered	Male, Age, Smoking	Any comorbidity, Hypertension, CVD, Diabetes, Chronic Lung Disease, Other	Fever, Fatigue, Myalgia, Cough, Sputum, Nausea, Diarrhoea	Respiratory Rate, Haemoglobin Levels 10
Zhou 2020 [62]	18/05/2020	China	Retrospective single-centre, case series	366	Severe (American Thoracic Society)	Non-severe (American Thoracic Society)	Male, Age	Hypertension, COPD, Diabetes	Fever, Fatigue, Cough, Dyspnoea	Respiratory Rate, Heart Rate, Oxygen saturation % 9



160 **Table 1.** Summary of studies included in quantitative synthesis. Abbreviations: ARDS, Acute respiratory distress syndrome; BMI, Body Mass Index; COPD, Chronic  
161 Obstructive Pulmonary Disease; CKD, Chronic Kidney Disease; CVD, Cardiovascular Disease; GI, Gastrointestinal; HIV, Human Immunodeficiency Virus; ICU, Intensive  
162 Care Unit; IMV, invasive mechanical intubation; mNOS, modified Newcastle Ottawa Scale; NHC, National Health Commission

163 Meta-analysis regression was carried out to investigate the pooled risk estimates of selected factors for  
164 severe outcome. Analysed patient characteristics included age >75, male sex, and severe obesity (BMI>40) (Fig.  
165 2). Age >75 years old was an important factor contributing to severe outcomes in COVID-19 (OR = 2.65 (1.81–  
166 3.90),  $I^2 = 51\%$ ). Males had higher risk compared to females (OR = 2.05 (1.39–3.04),  $I^2 = 75\%$ ). Severely obese  
167 individuals were at higher risk compared to non-severely obese individuals (OR = 2.57 (1.31–5.05),  $I^2 = 39\%$ ).  
168 When considering mortality as the outcome, the risk associated with age >75 is elevated further (OR = 5.57  
169 (3.10–10.00),  $I^2 = 28\%$ ) (S1 Fig.).

170 **Fig. 2.** Forest plot for the association of patient characteristics (age, sex, and severe obesity) with severe  
171 outcomes from COVID-19 using a random-effects model.

172 The risk associated with pre-existing conditions including hypertension, diabetes, active cancer, and chronic  
173 kidney disease (CKD) was also investigated using meta-analysis (Fig. 3). Active cancer (OR = 1.46 (1.04–2.04),  
174  $I^2 = 0\%$ ) was associated with increased risk of severe outcome. Diabetes (OR = 1.99 (0.92–4.29),  $I^2 = 43\%$ ),  
175 Hypertension (OR = 1.33 (0.99–1.80),  $I^2 = 63\%$ ), and CKD (OR = 1.27 (0.70–2.29),  $I^2 = 88\%$ ) showed no  
176 significant elevated risk. Forest plots showing meta-analysis regression for the relative risk of mortality  
177 conferred by hypertension, diabetes, and active cancer are reported in S2 Fig. To highlight the heterogeneity of  
178 reported outcomes in included studies, all reported risk estimates for male sex, diabetes and hypertension as  
179 presented as an example in the supplementary material (S3 Fig., S4 Fig. and S5 Fig. respectively).

180 **Fig. 3.** Forest plot for the association of comorbidities (diabetes, hypertension, chronic kidney disease, and  
181 active cancer) with severe outcomes from COVID-19 using a random-effects model.

182 Due to the heterogeneity of studies and insufficient comparable data, it was not possible to conduct meta-  
183 regression on all reported variables, including symptoms and vitals measurements. As such, pooled weighted  
184 estimates were extracted where possible (Table 2). Further patient characteristics such as blood type A and  
185 smoking history shows trends towards elevated risk for severe outcome (OR = 1.45, OR = 1.42, respectively). A  
186 number of symptoms suggested elevated risk of severe outcome including myalgia (4.82), sputum production  
187 (11.40), dyspnoea (8.68), nausea (15.55), and chills (6.32). Fever showed low estimated risk for both severity  
188 and mortality (1.06, 0.69 respectively). There was insufficient comparable data to estimate risk for cough as an  
189 independent factor, however, pooling univariate analysis also found low estimated risk for both severity and  
190 mortality (1.01, 1.08 respectively). There was limited evidence on loss of smell as a risk factor for severe  
191 outcomes [88].

**Table 2. Pooled risk estimates**

	Multivariate		Univariate	
	Severe	Mortality	Severe	Mortality
<b>Patient characteristics</b>				
Male	1.17	1.87	1.62	1.94
Age				
>60	1.69	3.15	3.75	3.04
>65	1.76	3.79	2.14	1.89
>75	1.93	5.82	-	2.41
BMI				
Obesity	1.69	1.45	2.02	-
Severe Obesity	2.07	1.51	1.80	-
Smoking				
Active	1.01	1.21	1.22	2.13
Former	1.31	-	1.26	0.56
History	1.42	0.83	0.79	2.06
Blood group				
O	0.68	-	1.14	-
A	1.45	-	1.32	-
<b>Comorbidities</b>				
Any condition	17.48	-	2.92	3.24
Hypertension	1.03	1.09	3.73	2.44
Cardiovascular Disease	1.09	1.53	3.37	4.04
Chronic arterial disease	0.94	2.14	2.71	2.85
Heart Failure	1.93	1.43	2.23	1.91
Chronic Heart Disease	1.52	-	2.24	5.75
Chronic Lung Disease	1.52	1.39	3.54	5.35
Asthma	0.75	-	0.97	0.85
COPD	1.01	2.05	2.47	2.68
Active Cancer	1.48	2.15	3.19	2.40
Immunosuppression	1.20	-	1.17	2.31
Chronic Kidney disease	1.39	1.15	3.50	2.79
<b>Symptoms</b>				
Fever	1.06	0.69	1.98	0.83
Fatigue	-	0.86	1.74	1.33
Myalgia	4.82	-	0.82	1.17
Cough	-	-	1.58	0.90
Sputum production	11.40	-	1.19	1.33
Dyspnoea	8.68	-	7.32	3.21
Chest pain	-	-	2.41	2.23
Nausea	15.55	-	1.37	0.72
Diarrhoea	-	-	1.20	0.89
Pharyngalgia	-	-	1.25	0.70
Headache	-	-	0.96	0.95
Dizziness	-	-	6.15	1.32
GI Symptoms	-	-	3.36	1.38
Chills	6.32	-	1.01	2.08
Loss of smell/taste	-	-	1.71	-
Rhinorrhoea	-	-	1.15	-
Anorexia	-	-	3.13	1.13
<b>Symptoms</b>				
Respiratory rate ( $\geq 24$ breaths/min)	-	-	11.60	4.50

192 **Table 2.** Pooled risk estimates for patient characteristics, comorbidities, and symptoms with adverse outcomes  
 193 of patients with COVID-19.

194 Respiratory rate  $\geq 24$  breaths/min was reported as a risk in five studies [23,44,48,65,72]. However, it was not  
 195 possible to combine data and provide estimates for risk due to heterogeneous outcomes and risk measures  
 196 reported, with a wide range in the effect estimates (OR = 1.74 (0.95-3.18) vs OR = 11.60 (3.34-40.27)). The  
 197 only study carrying out multivariable analysis for respiratory rate  $\geq 24$  breaths/min found increased risk with  
 198 reported OR of 2.00 (1.34-2.99) [65]. Similarly, there was insufficient data to report pooled estimates for  
 199 oxygen saturation. Two studies reported multivariate analysis for mortality as outcome, showing increased risk  
 200 with decreasing oxygen saturation, SpO<sub>2</sub> 88-92% (OR = 1.46 (1.18-1.79)) and SpO<sub>2</sub> <88% (OR = 2.00 (1.61-  
 201 2.48)) [74]. Xie et al. report that SpO<sub>2</sub>  $\leq 90\%$  was strongly associated with death, independently of age and sex  
 202 (Hazard Ratio, 47.41 (6.29 - 357.48) [51]. Univariate analysis also showed increased risk of severe outcome

203 with SpO<sub>2</sub> on admission to hospital <90% (OR = 3.83 (1.05-14.01)) [94] and <93% (OR = 13.12 (7.11-24.24))  
204 [23].

## 205 **Quality assessment**

206 Methodological structure and reporting of studies varied in quality. Quality scores were evaluated using an  
207 adapted version of the NOS [16], with an average quality score of 8.4 (SD = 1.7), ranging between 4 and 10  
208 (scale out of 10) (Table 1). All studies reported data collection from health records. Subject inclusion in reported  
209 literature was widely reported as hospital admission with positive RT-PCR test and, therefore, most studies  
210 show bias towards inclusion of hospitalised, thus more severe, patients. Few studies reported handling of  
211 missing data and bias reporting in findings.

## 212 **Publication bias**

213 Due to the high volume of published literature, we did not include publications in grey literature such as  
214 medRxiv and bioRxiv. Due to high heterogeneity and spread of data, we estimate risk of bias based on the most  
215 commonly reported variable: male sex (Fig. 4).

216 **Figure 4.** Funnel plot highlighting publication bias for male sex as risk factor for severe COVID-19 outcome. 1  
217 = Petrilli et al., 2020; 2 = Lassale et al., 2020; 3 = Price-Haywood et al., 2020; 4 = Huang et al., 2020b; 5 =  
218 Suleyman et al., 2020; 6 = Kalligeros et al., 2020; 7 = Simonnet et al., 2020; 8 = Palaiodimos et al., 2020; 9 =  
219 Chen et al. 2020; 10 = Shi et al., 2020; 11 = Zhang et al, 2020

## 220 **Discussion**

221 The findings of this systematic review and meta-analysis add to the growing body of evidence supporting the  
222 hypothesis that a large number of patient characteristics, comorbidities, symptoms, and vital signs parameters  
223 relate to increased risk of a severe outcome or death due to COVID-19.

224 Presented results align well with recent systematic reviews investigating risk factors in COVID-19,  
225 highlighting that age, sex, obesity, and multiple comorbidities increase the risk of adverse outcomes [33,61,98–  
226 100]. This study, however, goes further than previously available literature through our mapping of a wider  
227 variety of risk variables, including symptoms and vital signs.

228 Prior reported literature has made it clear that certain individuals are at higher risk than others. Hence, there  
229 has been a concerted effort to profile these high-risk individuals which has resulted in the development of a  
230 variety of diagnostic and prognostic models for COVID-19, with many reporting moderate to excellent  
231 discrimination [36,85]. Interpretation of early models, however, should be treated with caution as a result of the  
232 high risk of bias due to overfitting, lack of external validation, low representativeness of targeted populations,  
233 and subjective/proxy outcomes in criteria for hospitalisation and treatment [100,101]. These performance  
234 estimates may be misleading and, potentially, even harmful [100]. Efforts for future development of risk

235 profiling should follow standardised approaches such as the TRIPOD (Transparent reporting of a multivariable  
236 prediction model for individual prognosis or diagnosis) reporting guideline [102].

237 The identified risk factors align with current understanding of clinical pathophysiology for severe COVID-  
238 19. There are several theories as to why age is a significant risk factor for severe COVID-19. These include the  
239 role of comorbidities, as well as decreased efficiency of the immune system related to normal ageing [103].  
240 Male sex as a risk factor for severe disease is thought to result from a combination of the effect of health  
241 behaviours, sex hormone-mediated immune responses, and differential expression of ACE2 between sexes  
242 [104]. Obesity is a risk factor for development of comorbidities such as hypertension, CVD, and diabetes.  
243 However, there may be further involvement of obesity through metabolic consequences, which include  
244 increased circulating cytokine levels [105].

245 One study included in this review stands out due to its scale, investigating the primary care records of over  
246 17 million UK citizens [84]. Using a database of overwhelmingly unexposed individuals, the study can be  
247 differentiated from ours in that the risk associated with each variable confounds propensity for infection with the  
248 relative likelihood of death once infected. The resulting net risk weighting makes it unclear which of these two  
249 discrete probabilities is being affected by each variable. The limitation of this approach can be seen best with  
250 smoking status whereby the combined approach outputs a protective weighting, potentially due to the reported  
251 reduced infection risk conferred by active smoking, contrasting with our analysis which suggests increased  
252 prognostic risk (0.91 vs 1.21) [106]. Moreover, as the increased mortality risk of comorbidities was public  
253 knowledge before the first wave in the UK, it could be assumed that this demographic behaved more cautiously,  
254 resulting in the risk weightings being underestimated in the combined approach. Weightings for hypertension  
255 (0.88 [0.84–0.92] vs 1.08 [0.90–1.30]) and non-haematological cancer (using OpenSAFELY’s highest risk  
256 group; diagnosed <1-year ago 1.68 [1.46–1.94] vs our any-timeframe 2.15 [1.41–3.28]) seem to conform to this  
257 expectation. Both approaches, however, are uniquely useful in their application and, nevertheless, are largely in  
258 alignment in their outputs. Combining the discrete risks presents the foundation for the development of a risk  
259 model which can aid with the strategic planning required for health systems and the allocation of their resources.  
260 Our approach presents the foundation for a prognostic model which could support healthcare triage and be used  
261 on an individual level for comprehension of personal risk should one get infected.

## 262 **Limitations**

263 While our study presents pooled findings across 14 geographies and may be considered broadly  
264 representative of the pandemic, a number of limitations should be highlighted. The primary limitation is the high  
265 heterogeneity of the included studies. Notation of patients' highest level of care may be complex to interpret  
266 because such an endpoint is dependent on local policy and resources, which have been evolving in strategy and  
267 capacity since the onset of the pandemic. Thus, a recommendation of our study is for the development of  
268 standardised protocols for reporting of COVID-19 case series and retrospective analysis. Definition of the non-  
269 severe or comparator group is often poorly defined and is likely to result in sample selection bias towards more  
270 severe cases. Recent evidence from nationwide blanket testing suggests that 86.1% of individuals who tested  
271 positive for COVID-19 had none of the three main indicative symptoms of the illness, such as cough, fever, or a

272 loss of taste or smell [107]. In the majority of papers presented within this analysis, the individuals were already  
273 admitted to hospital, hence there is a strong selection bias towards those more severely affected and, as such, our  
274 results may underestimate the degree of risk. To facilitate rapid and widespread implementation of risk  
275 stratification, this investigation focused on risk factors that were easily obtainable. As such, we did not consider  
276 haematological risk factors within our review. These factors are known to be significant and may be valuable to  
277 include as part of risk stratification upon admission to hospital [108].

278 Confounding factors are highly likely in reported literature and, therefore, multivariate analysis is essential  
279 to determine causal risk factors. One such example of this is ethnicity. In our analysis of results, we chose to  
280 exclude estimates for risk relating to ethnicity and race due to the complex association of socio-economic  
281 factors and comorbidities which may be entangled with ethnicity. In early reports from the UK, there was  
282 significant disparity in outcomes for BAME (Black, Asian, and Minority Ethnic) communities [109]. However,  
283 in more recent analysis, it was found that the great majority of the increased risk of infection and death from  
284 COVID-19 among people from ethnic minorities can be explained by factors such as occupation, postcode,  
285 living situation, and pre-existing health conditions [110].

286 A further limitation of our study is the method used to pool risk estimates. We aimed to maximise the data  
287 collected by pulling all available estimates for risk of an associated variable. This method is flawed in that these  
288 outcomes are not directly comparable in a rigorous meta-analysis. Thus, caution is advised in interpretation of  
289 absolute risk for each variable of interest.

## 290 **Implications for future practice**

291 A key finding of the global analysis is the difficulty in combining data reported in the literature. Healthcare  
292 systems and researchers are, at present, not providing standardised recording and reporting of health data and  
293 outcomes. This heterogeneity in reporting limits the efficacy and impact of broad meta-analysis, as highlighted  
294 by the spread of data (Fig. 4). The use of standard case report forms, such as those outlined by the WHO may  
295 support this endeavour [111]. At a global level, if such data, anonymised and aggregated at patient level, is  
296 made more widely available, this could support the development of robust data-driven risk prediction models  
297 [112,113].

298 At regional and provider levels, evidence-based risk stratification could help plan resources and identify  
299 trends that predict areas with increased demand. Hospital admission of severe COVID-19 cases can be expected  
300 up to two weeks following onset of symptoms [14,114]. Hence, if risk stratification can be carried out in real-  
301 time and incorporate dynamic factors, including symptoms and vital signs, resources such as increased ICU  
302 capacity can be allocated strategically. Furthermore, through implementation of remote patient monitoring,  
303 patients can remain at home on a ‘virtual ward’ while under clinical observation. Early signs of clinical  
304 deterioration can be managed and, as a result, reduce hospital burden [115].

305 At the patient level, based on the findings of this study, it is recommended that individuals undergo  
306 comprehensive screening for risk factors including patient characteristics, detailed comorbidities, and reporting  
307 of real-time symptoms and vital sign measurements as part of a COVID-19 risk assessment. While some of the

308 variables identified in this review are well-known risk factors within the clinical or research domain, it is  
309 essential that this information is disseminated to the general public in an easily consumable format with  
310 supporting evidence and information. The pandemic has brought about significant social and economic  
311 disruption. Due to the lack of a prior evidence-base, current guidelines for individual risk management are blunt,  
312 broad generalisations. These may be sensitive to the majority of at-risk individuals, but simultaneously have low  
313 specificity, erroneously profiling large sections of the population. Thus, the concern is that many may lose  
314 confidence in these measures, including those correctly labelled ‘at-risk’. Providing individual patients with a  
315 comprehensive and individualised risk profile may empower individuals and increase engagement with public  
316 health messaging. This may facilitate efforts by national governments to encourage behaviour modification at a  
317 population level, in a manner which reduces the spread of the virus, thereby limiting socio-economic impact.

## 318 **Conclusion**

319 The findings of this paper highlight the range of factors associated with adverse outcomes in COVID-19,  
320 across severe disease, ICU admission, IMV, and death. The determination of critical risk factors may support  
321 risk stratification of individuals at multiple levels, from government policy, to clinical profiling at hospital  
322 admission, to individual behaviour change. This would enable both a more streamlined allocation of resources  
323 and provision of support to individuals who require them most. Future studies aimed at developing and  
324 validating robust prognostic models should look to follow a standardised approach to allow for comparability  
325 and sharing of knowledge. In this respect, a continuation of open data sharing is essential to facilitate  
326 improvement of these models.

## 327 **References**

- 328 1. WHO. Weekly epidemiological update - 17 November 2020. World Health Organization; 2020 Nov.  
329 Available: <https://www.who.int/publications/m/item/weekly-epidemiological-update---17-november-2020>
- 330 2. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical  
331 Course of Patients Infected With SARS-CoV-2 in Singapore. *JAMA*. 2020;323: 1488–1494.  
332 doi:10.1001/jama.2020.3204
- 333 3. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated  
334 with acute respiratory distress syndrome. *Lancet Respir Med*. 2020;8: 420–422. doi:10.1016/S2213-  
335 2600(20)30076-X
- 336 4. Lu X, Wang Y, Chen T, Wang J, Yan F. Classification of COVID-19 in intensive care patients. *Crit Care*.  
337 2020;24: 399. doi:10.1186/s13054-020-03127-7
- 338 5. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of  
339 coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis*. 2020;20: 669–677. doi:10.1016/S1473-  
340 3099(20)30243-7

- 341 6. Lopez M, Bell K, Annaswamy T, Juengst S, Ifejika N. COVID-19 Guide for the Rehabilitation Clinician:  
342 A Review of Nonpulmonary Manifestations and Complications. *Am J Phys Med Rehabil.* 2020;99: 669–673.  
343 doi:10.1097/phm.0000000000001479
- 344 7. Maxwell E. Living with Covid19. National Institute for Health Research; 2020 Oct.  
345 doi:10.3310/themedreview\_41169
- 346 8. Sheehy LM. Considerations for Postacute Rehabilitation for Survivors of COVID-19. *JMIR Public Health*  
347 *Surveill.* 2020;6: e19462. doi:10.2196/19462
- 348 9. Ferrer R. COVID-19 Pandemic: the greatest challenge in the history of critical care. *Med Intensiva Engl*  
349 *Ed.* 2020;44: 323–324. doi:10.1016/j.medine.2020.04.005
- 350 10. Iacobucci G. Covid-19: all non-urgent elective surgery is suspended for at least three months in England.  
351 *BMJ.* 2020; m1106. doi:10.1136/bmj.m1106
- 352 11. Lai AG, Pasa L, Banerjee A, Hall G, Denaxas S, Chang WH, et al. Estimated impact of the COVID-19  
353 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-  
354 time data on cancer care, cancer deaths and a population-based cohort study. *BMJ Open.* 2020;10: e043828.  
355 doi:10.1136/bmjopen-2020-043828
- 356 12. Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 9: Impact of non-  
357 pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. Imperial College  
358 London; 2020 Mar. doi:10.25561/77482
- 359 13. UK GOV. Government secures 5 million doses of Moderna vaccine. In: GOV.UK [Internet]. 16 Nov  
360 2020 [cited 18 Nov 2020]. Available: [https://www.gov.uk/government/news/government-secures-5-million-](https://www.gov.uk/government/news/government-secures-5-million-doses-of-moderna-vaccine)  
361 [doses-of-moderna-vaccine](https://www.gov.uk/government/news/government-secures-5-million-doses-of-moderna-vaccine)
- 362 14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult  
363 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395: 1054–1062.  
364 doi:10.1016/S0140-6736(20)30566-3
- 365 15. Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients  
366 infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.  
367 *BMJ.* 2020; m606. doi:10.1136/bmj.m606
- 368 16. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al. Panethnic Differences in  
369 Blood Pressure in Europe: A Systematic Review and Meta-Analysis. *PLOS ONE.* 2016;11: e0147601.  
370 doi:10.1371/journal.pone.0147601
- 371 17. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of  
372 Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic  
373 Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med.* 2019;200: e45–e67.  
374 doi:10.1164/rccm.201908-1581ST



- 375 18. National Health Commission of the People's Republic of China. Chinese Clinical Guidance for COVID-  
376 19 Pneumonia Diagnosis and Treatment (7th edition). [cited 13 Dec 2020]. Available:  
377 <http://kjfy.meetingchina.org/msite/news/show/cn/3337.html>
- 378 19. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R  
379 Foundation for Statistical Computing; 2019. Available: <http://www.R-project.org/>
- 380 20. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid*  
381 *Based Ment Health*. 2019;22: 153–160. doi:10.1136/ebmental-2019-300117
- 382 21. Cao J, Tu W-J, Cheng W, Yu L, Liu Y-K, Hu X, et al. Clinical Features and Short-term Outcomes of 102  
383 Patients with Corona Virus Disease 2019 in Wuhan, China. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020.  
384 doi:10.1093/cid/ciaa243
- 385 22. Chen L, Yu J, He W, Chen L, Yuan G, Dong F, et al. Risk factors for death in 1859 subjects with  
386 COVID-19. *Leukemia*. 2020;34: 2173–2183. doi:10.1038/s41375-020-0911-0
- 387 23. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients  
388 with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368: m1091. doi:10.1136/bmj.m1091
- 389 24. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in  
390 Shanghai, China. *J Infect*. 2020;80: e1–e6. doi:10.1016/j.jinf.2020.03.004
- 391 25. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to  
392 SARS-CoV-2: A multicenter study during the COVID-19 outbreak. *Cancer Discov*. 2020;10: 783.  
393 doi:10.1158/2159-8290.CD-20-0422
- 394 26. Deng Y, Liu W, Liu K, Fang Y-Y, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered  
395 cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. *Chin Med J (Engl)*. 2020;133: 1261–  
396 1267. doi:10.1097/CM9.0000000000000824
- 397 27. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with  
398 COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J*. 2020;55.  
399 doi:10.1183/13993003.00524-2020
- 400 28. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities: A Multicenter  
401 Study of Clinical Features. *Am J Respir Crit Care Med*. 2020;201: 1380–1388. doi:10.1164/rccm.202002-  
402 0445OC
- 403 29. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590  
404 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J*. 2020;55. doi:10.1183/13993003.00547-  
405 2020

- 406 30. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more  
407 severe disease: a multicenter retrospective observational study. *Hypertens Res.* 2020. doi:10.1038/s41440-020-  
408 0485-2
- 409 31. Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. Clinical findings of patients with coronavirus  
410 disease 2019 in Jiangsu province, China: A retrospective, multi-center study. *PLoS Negl Trop Dis.* 2020;14:  
411 e0008280. doi:10.1371/journal.pntd.0008280
- 412 32. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological  
413 characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.  
414 *Gut.* 2020;69: 1002–1009. doi:10.1136/gutjnl-2020-320926
- 415 33. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic  
416 review and meta-analysis of clinical characteristics, risk factors, and outcomes. *J Med Virol.* 2020;n/a.  
417 doi:<https://doi.org/10.1002/jmv.26424>
- 418 34. Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher  
419 risk of mortality than known diabetes in hospitalized patients with COVID-19. *Diabetes Obes Metab.* 2020.  
420 doi:10.1111/dom.14099
- 421 35. Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, et al. Serum Amyloid A is a biomarker of severe  
422 Coronavirus Disease and poor prognosis. *J Infect.* 2020;80: 646–655. doi:10.1016/j.jinf.2020.03.035
- 423 36. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and Validation of a Clinical Risk  
424 Score to Predict the Occurrence of Critical Illness in Hospitalized Patients with COVID-19. *JAMA Intern Med.*  
425 2020. doi:10.1001/jamainternmed.2020.2033
- 426 37. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and  
427 procalcitonin in patients with COVID-19. *J Clin Virol.* 2020;127: 104370. doi:10.1016/j.jcv.2020.104370
- 428 38. Liu F, Zhang Q, Huang C, Shi C, Wang L, Shi N, et al. CT quantification of pneumonia lesions in early  
429 days predicts progression to severe illness in a cohort of COVID-19 patients. *Theranostics.* 2020;10: 5613–  
430 5622. doi:10.7150/thno.45985
- 431 39. Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal Involvement and Early Prognosis in Patients  
432 with COVID-19 Pneumonia. *J Am Soc Nephrol.* 2020;31: 1157–1165. doi:10.1681/ASN.2020030276
- 433 40. Qin C, Zhou L, Hu Z, Yang S, Zhang S, Chen M, et al. Clinical Characteristics and Outcomes of  
434 COVID-19 Patients with a History of Stroke in Wuhan, China. *Stroke.* 2020; 2219–2223.  
435 doi:10.1161/STROKEAHA.120.030365
- 436 41. Ren H, Yang Y, Wang F, Yan Y, Shi X, Dong K, et al. Association of the insulin resistance marker TyG  
437 index with the severity and mortality of COVID-19. *Cardiovasc Diabetol.* 2020;19: 58. doi:10.1186/s12933-  
438 020-01035-2

- 439 42. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on  
440 an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020;46: 846–848.  
441 doi:10.1007/s00134-020-05991-x
- 442 43. Shi Q, Zhang X, Jiang F, Hu N, Bimu C, Feng J, et al. Clinical Characteristics and Risk Factors for  
443 Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. *Diabetes*  
444 *Care.* 2020;43: 1382–1391. doi:10.2337/dc20-0598
- 445 44. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and  
446 establishment of a host risk score: findings of 487 cases outside Wuhan. *Crit Care.* 2020;24: 108.  
447 doi:10.1186/s13054-020-2833-7
- 448 45. Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, et al. Clinical course and outcome of 107 patients  
449 infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. *Crit Care.*  
450 2020;24: 188. doi:10.1186/s13054-020-02895-6
- 451 46. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients  
452 with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc.* 2020;323:  
453 1061–1069. doi:10.1001/jama.2020.1585
- 454 47. Wang R, Pan M, Zhang X, Han M, Fan X, Zhao F, et al. Epidemiological and clinical features of 125  
455 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. *Int J Infect Dis.* 2020;95: 421–428.  
456 doi:10.1016/j.ijid.2020.03.070
- 457 48. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients:  
458 Characteristics and prognostic factors based on 4-week follow-up. *J Infect.* 2020;80: 639–645.  
459 doi:10.1016/j.jinf.2020.03.019
- 460 49. Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical Course and Outcomes of 344 Intensive Care  
461 Patients with COVID-19. *Am J Respir Crit Care Med.* 2020;201: 1430–1434. doi:10.1164/rccm.202003-  
462 0736LE
- 463 50. Wu F, Zhou Y, Wang Z, Xie M, Shi Z, Tang Z, et al. Clinical characteristics of COVID-19 infection in  
464 chronic obstructive pulmonary disease: A multicenter, retrospective, observational study. *J Thorac Dis.* 2020;12:  
465 1811–1823. doi:10.21037/jtd-20-1914
- 466 51. Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G, et al. Association Between Hypoxemia and Mortality  
467 in Patients With COVID-19. *Mayo Clin Proc.* 2020;95: 1138–1147. doi:10.1016/j.mayocp.2020.04.006
- 468 52. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients  
469 with severe covid-19 with diabetes. *BMJ Open Diabetes Res Care.* 2020;8. doi:10.1136/bmjdr-2020-001343
- 470 53. Yang L, Liu J, Zhang R, Li M, Li Z, Zhou X, et al. Epidemiological and clinical features of 200  
471 hospitalized patients with corona virus disease 2019 outside Wuhan, China: A descriptive study. *J Clin Virol.*  
472 2020;129. doi:10.1016/j.jcv.2020.104475

- 473 54. Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. A retrospective study of risk factors for severe  
474 acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients. *Pol Arch Intern Med.*  
475 2020;130: 390–399. doi:10.20452/pamw.15312
- 476 55. Ye C, Zhang S, Zhang X, Cai H, Gu J, Lian J, et al. Impact of comorbidities on patients with COVID-19:  
477 A large retrospective study in Zhejiang, China. *J Med Virol.* 2020. doi:10.1002/jmv.26183
- 478 56. Yu Q, Wang Y, Huang S, Liu S, Zhou Z, Zhang S, et al. Multicenter cohort study demonstrates more  
479 consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients.  
480 *Theranostics.* 2020;10: 5641–5648. doi:10.7150/thno.46465
- 481 57. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and short-term outcomes of 221  
482 patients with COVID-19 in Wuhan, China. *J Clin Virol.* 2020;127: 104364. doi:10.1016/j.jcv.2020.104364
- 483 58. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and  
484 mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol Infect.* 2020;26: 767–772.  
485 doi:10.1016/j.cmi.2020.04.012
- 486 59. Zhang J, Yu M, Tong S, Liu LY, Tang LV. Predictive factors for disease progression in hospitalized  
487 patients with coronavirus disease 2019 in Wuhan, China. *J Clin Virol.* 2020;127: 104392.  
488 doi:10.1016/j.jcv.2020.104392
- 489 60. Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, et al. Epidemiological, clinical characteristics of cases of  
490 SARS-CoV-2 infection with abnormal imaging findings. *Int J Infect Dis.* 2020;94: 81–87.  
491 doi:10.1016/j.ijid.2020.03.040
- 492 61. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases:  
493 A systematic literature review and meta-analysis. *J Infect.* 2020;81: e16–e25. doi:10.1016/j.jinf.2020.04.021
- 494 62. Zhou Y, He Y, Yang H, Yu H, Wang T, Chen Z, et al. Development and validation a nomogram for  
495 predicting the risk of severe COVID-19: A multi-center study in Sichuan, China. *PLoS One.* 2020;15:  
496 e0233328. doi:10.1371/journal.pone.0233328
- 497 63. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and  
498 clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. *BMJ.*  
499 2020;369: m1996. doi:10.1136/bmj.m1996
- 500 64. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology,  
501 clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort  
502 study. *Lancet.* 2020;395: 1763–1770. doi:10.1016/S0140-6736(20)31189-2
- 503 65. D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics  
504 and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative  
505 cohort study from a US “hot spot.” *Ann Rheum Dis.* 2020. doi:10.1136/annrheumdis-2020-217888

- 506 66. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death  
507 in Critically Ill Patients With Coronavirus Disease 2019 in the US. *JAMA Intern Med.* 2020.  
508 doi:10.1001/jamainternmed.2020.3596
- 509 67. Hajifathalian K, Kumar S, Newberry C, Shah S, Fortune B, Krisko T, et al. Obesity is associated with  
510 worse outcomes in COVID-19: Analysis of Early Data From New York City. *Obesity.* 2020;n/a.  
511 doi:10.1002/oby.22923
- 512 68. Imam Z, Odish F, Gill I, O'Connor D, Armstrong J, Vanood A, et al. Older age and comorbidity are  
513 independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. *J*  
514 *Intern Med.* 2020;n/a. doi:10.1111/joim.13119
- 515 69. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of Obesity  
516 with Disease Severity Among Patients with Coronavirus Disease 2019. *Obesity.* 2020;28: 1200–1204.  
517 doi:10.1002/oby.22859
- 518 70. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk Factors for Intensive Care  
519 Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus  
520 Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). *Clin Infect Dis.*  
521 2020. doi:10.1093/cid/ciaa1012
- 522 71. Latz CA, DeCarlo C, Boitano L, Png CYM, Patell R, Conrad MF, et al. Blood type and outcomes in  
523 patients with COVID-19. *Ann Hematol.* 2020. doi:10.1007/s00277-020-04169-1
- 524 72. Okoh AK, Sossou C, Dangayach NS, Meledathu S, Phillips O, Raczek C, et al. Coronavirus disease 19 in  
525 minority populations of Newark, New Jersey. *Int J Equity Health.* 2020;19: 93. doi:10.1186/s12939-020-01208-  
526 1
- 527 73. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity is  
528 associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York.  
529 *Metabolism.* 2020;108. doi:10.1016/j.metabol.2020.154262
- 530 74. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with  
531 hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City:  
532 prospective cohort study. *BMJ.* 2020;369: m1966. doi:10.1136/bmj.m1966
- 533 75. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and  
534 White Patients with Covid-19. *N Engl J Med.* 2020;382: 2534–2543. doi:10.1056/NEJMsa2011686
- 535 76. Ramlall V, Thangaraj PM, Meydan C, Foox J, Butler D, Kim J, et al. Immune complement and  
536 coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. *Nat Med.* 2020. doi:10.1038/s41591-  
537 020-1021-2

- 538 77. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical Characteristics and  
539 Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. *JAMA*  
540 *Netw Open*. 2020;3: e2012270. doi:10.1001/jamanetworkopen.2020.12270
- 541 78. Giacomelli A, Ridolfo AL, Milazzo L, Oreni L, Bernacchia D, Siano M, et al. 30-day mortality in  
542 patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study.  
543 *Pharmacol Res*. 2020;158. doi:10.1016/j.phrs.2020.104931
- 544 79. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics  
545 and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.  
546 *JAMA - J Am Med Assoc*. 2020;323: 1574–1581. doi:10.1001/jama.2020.5394
- 547 80. Masetti C, Generali E, Colapietro F, Voza A, Cecconi M, Messina A, et al. High mortality in COVID-19  
548 patients with mild respiratory disease. *Eur J Clin Invest*. 2020. doi:10.1111/eci.13314
- 549 81. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al. Genomewide  
550 Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med*. 2020.  
551 doi:10.1056/NEJMoa2020283
- 552 82. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK  
553 patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective  
554 observational cohort study. *BMJ*. 2020;369: m1985. doi:10.1136/bmj.m1985
- 555 83. Lassale C, Gaye B, Hamer M, Gale CR, Batty GD. Ethnic disparities in hospitalisation for COVID-19 in  
556 England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a  
557 community-based cohort study. *Brain Behav Immun*. 2020;88: 44–49. doi:10.1016/j.bbi.2020.05.074
- 558 84. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with  
559 COVID-19-related death using OpenSAFELY. *Nature*. 2020. doi:10.1038/s41586-020-2521-4
- 560 85. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A,  
561 Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and  
562 Diabetes to COVID-19 Outcomes in Mexico. *J Clin Endocrinol Metab*. 2020;105. doi:10.1210/clinem/dgaa346
- 563 86. Kammar-García A, Vidal-Mayo JJ, Vera-Zertuche JM, Lazcano-Hernández M, Vera-López O, Segura-  
564 Badilla O, et al. IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A  
565 RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT. *Rev Investig Clin Organo Hosp Enfermedades*  
566 *Nutr*. 2020;72: 151–158. doi:10.24875/RIC.20000207
- 567 87. Hou W, Zhang W, Jin R, Liang L, Xu B, Hu Z. Risk factors for disease progression in hospitalized  
568 patients with COVID-19: a retrospective cohort study. *Infect Lond*. 2020;52: 498–505.  
569 doi:10.1080/23744235.2020.1759817
- 570 88. Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19  
571 Patients. *J Korean Med Sci*. 2020;35: e174. doi:10.3346/jkms.2020.35.e174

- 572 89. Göker H, Aladağ-Karakulak E, Demiroğlu H, Ayaz CM, Büyükaşık Y, İnkaya AC, et al. The effects of  
573 blood group types on the risk of COVID-19 infection and its clinical outcome. *Turk J Med Sci.* 2020;50: 679–  
574 683. doi:10.3906/sag-2005-395
- 575 90. Baqui P, Bica I, Marra V, Ercole A, van der Schaar M. Ethnic and regional variations in hospital  
576 mortality from COVID-19 in Brazil: a cross-sectional observational study. *Lancet Glob Health.* 2020;8: e1018–  
577 e1026. doi:10.1016/S2214-109X(20)30285-0
- 578 91. Israelsen SB, Kristiansen KT, Hindsberger B, Ulrik CS, Andersen O, Jensen M, et al. Characteristics of  
579 patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020. *Dan Med J.* 2020;67.
- 580 92. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High Prevalence of  
581 Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical  
582 Ventilation. *Obesity.* 2020;28: 1195–1199. doi:10.1002/oby.22831
- 583 93. Itelman E, Wasserstrum Y, Segev A, Avaky C, Negru L, Cohen D, et al. Clinical Characterization of 162  
584 COVID-19 patients in Israel: Preliminary Report from a Large Tertiary Center. *Isr Med Assoc J.* 2020;22: 271–  
585 274.
- 586 94. Shahriarirad R, Khodamoradi Z, Erfani A, Hosseinpour H, Ranjbar K, Emami Y, et al. Epidemiological  
587 and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. *BMC Infect Dis.*  
588 2020;20. doi:10.1186/s12879-020-05128-x
- 589 95. Nowak B, Szymański P, Pańkowski I, Szarowska A, Życińska K, Rogowski W, et al. Clinical  
590 characteristics and short-term outcomes of patients with coronavirus disease 2019: a retrospective single-center  
591 experience of a designated hospital in Poland. *Pol Arch Intern Med.* 2020;130: 407–411.  
592 doi:10.20452/pamw.15361
- 593 96. Li Q, Cao Y, Chen L, Wu D, Yu J, Wang H, et al. Hematological features of persons with COVID-19.  
594 *Leukemia.* 2020;34: 2163–2172. doi:10.1038/s41375-020-0910-1
- 595 97. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona  
596 virus disease 2019 (COVID-19) in Changsha. *Eur Rev Med Pharmacol Sci.* 2020;24: 3404–3410.  
597 doi:10.26355/eurrev\_202003\_20711
- 598 98. Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and  
599 comorbidities: a systematic review and meta-analysis. *Postgrad Med.* 2020;0: 1–7.  
600 doi:10.1080/00325481.2020.1786964
- 601 99. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured  
602 literature review. *Infection.* 2020; 1–14. doi:10.1007/s15010-020-01509-1
- 603 100. Wynants L, Calster BV, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for  
604 diagnosis and prognosis of covid-19: systematic review and critical appraisal. *BMJ.* 2020;369.  
605 doi:10.1136/bmj.m1328

- 606 101. Al Hassan H, Cocks E, Jesani L, Lewis S, Szakmany T. Clinical Risk Prediction Scores in Coronavirus  
607 Disease 2019: Beware of Low Validity and Clinical Utility. *Crit Care Explor.* 2020;2.  
608 doi:10.1097/CCE.0000000000000253
- 609 102. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent  
610 Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and  
611 elaboration. *Ann Intern Med.* 2015;162: W1-73. doi:10.7326/M14-0698
- 612 103. Mahase E. Covid-19: What do we know about “long covid”? *BMJ.* 2020;370. doi:10.1136/bmj.m2815
- 613 104. Kelada M, Anto A, Dave K, Saleh SN. The Role of Sex in the Risk of Mortality From COVID-19  
614 Amongst Adult Patients: A Systematic Review. *Cureus.* 2020;12. doi:10.7759/cureus.10114
- 615 105. Mahase E. Covid-19: Why are age and obesity risk factors for serious disease? *BMJ.* 2020;371.  
616 doi:10.1136/bmj.m4130
- 617 106. Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among  
618 hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? *Intern Emerg Med.* 2020; 1–8.  
619 doi:10.1007/s11739-020-02355-7
- 620 107. Petersen I, Phillips A. Three Quarters of People with SARS-CoV-2 Infection are Asymptomatic:  
621 Analysis of English Household Survey Data. *Clin Epidemiol.* 2020;Volume 12: 1039–1043.  
622 doi:10.2147/CLEP.S276825
- 623 108. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, et al. Haematological characteristics and risk factors in  
624 the classification and prognosis evaluation of COVID-19: a retrospective cohort study. *Lancet Haematol.*  
625 2020;7: e671–e678. doi:10.1016/S2352-3026(20)30217-9
- 626 109. Public Health England. Beyond the Data: Understanding the Impact of COVID-19 on BAME  
627 Communities. 2020 Jun.
- 628 110. UK GOV. Quarterly report on progress to address COVID-19 health inequalities. Race Disparity Unit,  
629 Cabinet Office; 2020 Oct. Available: [https://www.gov.uk/government/publications/quarterly-report-on-](https://www.gov.uk/government/publications/quarterly-report-on-progress-to-address-covid-19-health-inequalities)  
630 [progress-to-address-covid-19-health-inequalities](https://www.gov.uk/government/publications/quarterly-report-on-progress-to-address-covid-19-health-inequalities)
- 631 111. WHO. Global COVID-19 Clinical Platform: Rapid core case report form (CRF). World Health  
632 Organization; 2020 Aug. Report No.: WHO/2019-nCoV/Clinical\_CRF/2020.4. Available:  
633 [https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Clinical\\_CRF-2020.4](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Clinical_CRF-2020.4)
- 634 112. Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al. Living risk  
635 prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults:  
636 national derivation and validation cohort study. *BMJ.* 2020;371. doi:10.1136/bmj.m3731



637 113. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted  
638 to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and  
639 validation of the 4C Mortality Score. *BMJ*. 2020;370. doi:10.1136/bmj.m3339

640 114. CO-CIN. COVID-19 - Time from symptom onset until death in UK hospitalised patients, 7 October  
641 2020. Scientific Advisory Group for Emergencies; 2020 Oct. Available:  
642 [https://www.gov.uk/government/publications/co-cin-covid-19-time-from-symptom-onset-until-death-in-uk-](https://www.gov.uk/government/publications/co-cin-covid-19-time-from-symptom-onset-until-death-in-uk-hospitalised-patients-7-october-2020)  
643 [hospitalised-patients-7-october-2020](https://www.gov.uk/government/publications/co-cin-covid-19-time-from-symptom-onset-until-death-in-uk-hospitalised-patients-7-october-2020)

644 115. Thornton J. The “virtual wards” supporting patients with covid-19 in the community. *BMJ*. 2020;369.  
645 doi:10.1136/bmj.m2119

646 **Supporting information**

647 **S1 Fig.** Forest plot for the association of patient characteristics between age and sex, and mortality in COVID-  
648 19 using a random-effects model.

649 **S2 Fig.** Forest plot for the association of comorbidities, between diabetes, hypertension and active cancer, and  
650 mortality in COVID-19 using a random-effects model.

651 **S3 Fig.** Reported risk estimates for male sex. Size of the circle indicates sample size represented.

652 **S4 Fig.** Reported risk estimates for any diabetes. Size of the circle indicates sample size represented.

653 **S5 Fig.** Reported risk estimates for any hypertension. Size of the circle indicates sample size represented.

654

<b>S1 Table. Search terms</b>
<b>Search strategy (PICO)</b>
1. COVID-19 [Supplementary Concept] 2. (ventilator OR ICU OR intensive care OR MODSOR ARDS OR severity OR prognosis OR hospitalis* OR hospitaliz* OR intubation OR ventilation OR admission* OR admitted OR "critical care" OR "critical cases"OR severe) [Title/Abstract] 3.(clinical OR symptom* OR characteristic* OR comorbidit* OR "co morbidit*" OR "risk factors" OR predict*) [Title/Abstract] 4 (pediatric* OR paediatric* OR child*)[Title/Abstract] 5. ("2020/01/01"[Date - Publication] : "3000"[Date - Publication]) 1 AND 2 AND 3 AND 5 NOT 4
<b>Search terms for PubMed</b>
(((((COVID-19[Supplementary Concept]) AND ((ventilator[Title/Abstract] OR ICU[Title/Abstract] OR intensive care[Title/Abstract] OR mortality[Title/Abstract] OR prognosis[Title/Abstract] "MODS"[Title/Abstract] OR ARDS[Title/Abstract] OR severity[Title/Abstract] OR prognosis[Title/Abstract] OR hospitalis*[Title/Abstract] OR hospitaliz*[Title/Abstract] OR "respiratory failure"[Title/Abstract] OR intubation[Title/Abstract] OR ventilation[Title/Abstract] OR admission*[Title/Abstract] OR admitted[Title/Abstract] OR "critical care"[Title/Abstract] OR "critical cases"[Title/Abstract] OR severe)[Title/Abstract])) AND ((clinical[Title/Abstract] OR symptom*[Title/Abstract] OR characteristic*[Title/Abstract] OR comorbidit*[Title/Abstract] OR "co morbidit*" [Title/Abstract] OR risk[Title/Abstract] OR predict*) [Title/Abstract])) NOT ((pediatric*[Title/Abstract] OR paediatric*[Title/Abstract] OR child*) [Title/Abstract])) AND (("2020/01/01"[Date - Publication] : "3000"[Date - Publication])) Filters: English Sort by: Most Recent
<b>Search terms for Scopus</b>
(TITLE-ABS-KEY ( ncov* OR coronavirus OR "SARS-CoV-2" OR covid-19 OR covid ) AND TITLE-ABS-KEY ( ventilator OR icu OR intensive AND care OR mortality OR prognosis "MODS" OR ards OR severity OR prognosis OR hospitalis* OR hospitaliz* OR "respiratory failure" OR intubation OR ventilation OR admission* OR admitted OR "critical care" OR "critical cases" ) AND TITLE-ABS-KEY ( clinical OR symptom* OR characteristic* OR comorbidit* OR "co morbidit*"OR risk OR predict* ) AND NOT TITLE-ABS-KEY ( pediatric* OR paediatric* OR child* ) ) AND DOCTYPE ( ar OR re ) AND PUBYEAR > 2019

655 **S1 Table.** Systematic literature review search terms and strategy.

656

657


658

659

660

661


**END OF MANUSCRIPT**



## Age >75 years old

Source	OR (95% CI)
Chen2020	6.67 [1.00; 44.49]
Shi2020	6.67 [2.62; 16.98]
Hou2020	6.88 [0.38; 124.56]
Petrilli2020	2.32 [1.57; 3.43]
Kalligeros2020	2.62 [1.00; 6.86]
Palaiodimos2020	2.62 [1.00; 6.86]
Simonnet2020	1.00 [0.37; 2.70]
Huang2020	4.75 [2.62; 8.61]
Lassale2020	1.91 [1.38; 2.64]
Price-Haywood2020	2.06 [1.88; 2.26]
Total (fixed effect)	2.12 [1.95; 2.30]
Total (random effects)	2.65 [1.81; 3.90]


Heterogeneity:  $\chi^2_3 = 18.42$  ( $P = .03$ ),  $I^2 = 51\%$



## Male

Source	OR (95% CI)
Chen2020	3.38 [0.77; 14.84]
Shi2020	3.68 [1.75; 7.74]
Zhang2020	24.80 [1.80; 341.67]
Petrilli2020	1.06 [0.85; 1.32]
Suleyman2020	2.00 [1.30; 3.08]
Kalligeros2020	2.40 [0.87; 6.62]
Palaiodimos2020	2.96 [1.35; 6.49]
Simonnet2020	2.83 [1.02; 7.85]
Huang2020	1.91 [1.17; 3.12]
Lassale2020	1.15 [0.93; 1.42]
Price-Haywood2020	1.79 [1.54; 2.08]
Total (fixed effect)	1.53 [1.38; 1.69]
Total (random effects)	2.05 [1.39; 3.04]


Heterogeneity:  $\chi^2_{10} = 39.87$  ( $P < .001$ ),  $I^2 = 75\%$



## Severe Obesity


Source	OR (95% CI)
Petrilli2020	1.71 [1.10; 2.66]
Suleyman2020	2.00 [1.40; 2.86]
Kalligeros2020	5.39 [1.13; 25.71]
Simonnet2020	7.36 [1.63; 33.23]
Total (fixed effect)	2.03 [1.55; 2.65]
Total (random effects)	2.57 [1.31; 5.05]

Heterogeneity:  $\chi^2_3 = 4.89$  ( $P = .18$ ),  $I^2 = 39\%$




## Diabetes

Source	OR (95% CI)
Huang2020	4.33 [1.06; 17.69]
Hou2020	64.13 [4.59; 895.96]
Petrilli2020	1.23 [0.99; 1.53]
Suleyman2020	1.30 [0.80; 2.11]
Kalligeros2020	1.91 [0.71; 5.14]
Palaiodimos2020	1.40 [0.66; 2.97]
Simonnet2020	1.60 [0.44; 5.82]
Kammar-García2020	1.40 [1.20; 1.63]
Total (fixed effect)	1.37 [1.22; 1.54]
Total (random effects)	1.99 [0.92; 4.29]
Heterogeneity: $\chi^2_7 = 12.30$ ( $P = .09$ ), $I^2 = 43\%$	




## Hypertension

Source	OR (95% CI)
Shi2020	2.71 [1.32; 5.56]
Hou2020	2.98 [0.77; 11.53]
Petrilli2020	0.96 [0.75; 1.23]
Suleyman2020	1.00 [0.50; 2.00]
Kalligeros2020	0.79 [0.27; 2.31]
Simonnet2020	2.29 [0.89; 5.89]
Kammar-García2020	1.40 [1.20; 1.63]
Huang2020	1.56 [0.93; 2.62]
Lassale2020	1.02 [0.87; 1.20]
Total (fixed effect)	1.19 [1.08; 1.31]
Total (random effects)	1.33 [0.99; 1.80]
Heterogeneity: $\chi^2_8 = 21.27$ ( $P = .006$ ), $I^2 = 62\%$	



## Active cancer

Source	OR (95% CI)
Petrilli2020	1.30 [0.95; 1.78]
Suleyman2020	1.90 [1.00; 3.61]
Dai2020	1.99 [0.53; 7.47]
Total (fixed effect)	1.42 [1.08; 1.87]
Total (random effects)	1.46 [1.04; 2.04]
Heterogeneity: $\chi^2_2 = 1.35$ ( $P = .51$ ), $I^2 = 0\%$	



## Chronic Kidney Disease

Source	OR (95% CI)
Petrilli2020	0.73 [0.55; 0.97]
Suleyman2020	2.00 [1.30; 3.08]
Kammar-García2020	1.50 [0.90; 2.50]
Total (fixed effect)	1.06 [0.86; 1.32]
Total (random effects)	1.27 [0.70; 2.29]
Heterogeneity: $\chi^2_2 = 16.78$ ( $P < .001$ ), $I^2 = 88\%$	

